Christina Appenzeller

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

Melissa L. Johnson, Zanete Zvirbule, Åslaug Helland et al. · Journal of Thoracic Oncology · 2021 · 147 citations · Full text

The novel  2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Marianne Kraus, Jürgen Bader, Paul P. Geurink et al. · Haematologica · 2015 · 47 citations · Full text

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Yannis Metaxas, Martin Früh, E.I. Eboulet et al. · Annals of Oncology · 2020 · 32 citations · Full text

Surgical Oncology, Malignant Pleural Mesothelioma, Medicine +6

Sotorasib Shows Intracranial Activity in Patients with <b><i>KRAS G12C-</i></b>Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases

Kira‐Lee Koster, Christina Appenzeller, Arno Lauber et al. · Case Reports in Oncology · 2022 · 21 citations · Full text